Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.05/.06 inching up
Would've averaged down if I had any confidence in Chinese companies.
I was in this one before, and dumped it a while back.... looks like it might be time to wade back into the water.
Do those of you who have been following this one think they will file soon, with the new auditor in place?
Yeah, I averaged down at .08. Not looking too good for now, but things can change fast.
.034 on the ask.
I'm thinking the same way about the final flush.
Unfortunately I bought months ago at .15 thinking that was the final flush.
Yes, no doubt and investors have all the reasons to be bearish on these stocks.
I just wonder if this is the final flush before they file? Stocks like these tend to get flushed to the bottom before good news hits...
They need to refile statements with corrections. Then it'll go to .50+
I guess the market doesn't believe they'll file
yeah. WTF?? Ask is up to .04, somebody mopped up a bunch of CHEAP stock. L2 shows the ask at .48 after the .04's!?!?!
Absolutely INSANE sector here with these china junk microcaps. NOTHING would surprise me...not even seeing HFGB trade up to .48 soon. Ten baggers+ off long term lows are not that rare in this asylum of a sector.
L2 looks better again...increased volume on the bid side... little showing on the ask volume per tdameritrades' L2...
Come on HFGB...I'm watching for at least a triple before locking in free shares for the long haul on this GAMBLE china junk!
when they file again this will run huge... bulk of shares were sold around .70
patience....
Now there are plenty of shares at the .08 ask. Not much hope for a rally today...
That was part of what a couple of conference attendees took away from HFGB in person too.
And, business sounds like it's going great. Numbers should change little per mgt...and business is booming.
Recipe for a ten bagger++ off the recent lows.... I HOPE.
I'll sell some shares into any nice volume rally...taking a free position in the form of free shares as profit from swing trading. I don't mind selling some on the way up, too early...if it means I get to ride stress free to the upside on a potential 20 bagger++++.
I've had some contact with management at HFGB (one email) in the last two months. I interpreted their comments as meaning that everything was fine, business was good, and they were working on their numbers with the new accounting firm.
I'm holding my shares.
Thin again on the .10 ask. Bid is larger at .08, but I'm glad to see no sellers.
Come on HFGB, how about a rally already. Appears deeply oversold based on TA... could triple with simple confidence in the legitimacy of the co.
Posters on Yahoo...I hope they are truthful, if so, we'll be making huge gains on HFGB.
.08 bid. .10 ask. Big bid, thin ask... appears this pink sheet is ripening for a run up?!?!?!
Info on Yahoo from someone who attended the conference indicates HFGB is just fine. .12 on the ask, anything can happen, could be we have one that's about to triple in a heartbeat?!?!?!
Huge bid ask spread...modest buying could have this back above .20??
So much for an honest china man. Website down. 500K on the ask.
What a despicable display of corruption.
Rising bid could be related to HFGB attending the trade show??
Might new clients and new investors positively impact HFGB near term? There's just a little resistance at .10...but some modest accumulation could zip this up to .30+ imo.
.10 last trade. HFGB finally starting to move. A big breakout here would bring it up to way undervalued, from grossly undervalued. LOL,
Assuming the co. is on the up and up, good accounting etc.
.099 on the ask...little volume available on the ask...slowly the environment is improving for china small caps.
This one could be a near term multi-bagger.
Raise those ask prices!
Very little volume showing on L2 at the ask now for HFGB.
Buy some and let her run!
Very good to see! I went to Yahoo finance, clicked on the co. web site link and got what appeared to be a soft porn site.
While that could be very profitable...it's not what I care to invest in. LOL.
Yahoo needs to fix something maybe!!??
Now, let's see HFGB triple from .08!!
tdameritrade clients will have to call into a broker to get a buy order placed, although my experience is that folks won't do that until the price is way higher and volume picks up.
Web site works for me. HFGB. I emailed Bing (IR) on Friday and will let you know if/when I receive a response.
Wierd for sure...hope that gets fixed.
Nothing but accumulation yesterday for HFGB. Only two buys though. LOL. Sleeper stock ready to rally 500%??
On the plus side, nobody was dumping into the news yesterday. Not a pump n dump press release. Good to see the bid ask spread tighten too.
Only thing that makes sense to me is to buy "low", sell enough on the way up to ride free shares long term...and repeat repeat repeat. I'm up to over 115 of these china crap stocks now. For awhile they were golden...but stinky dung now! Buy em when nobody wants em....take some off the table when the crowd piles in.
Again, very little volume has gone thru at below .08. The chart is nasty, but I keep hoping to catch some of these china "thrown out babies" near the low, just before they pop. I missed WH at .23...a few days later. .55! Damn.
GL fellow gamblers. With HFGB attending a trade show, lots of small cap investors might like what they see...even modest low volume,low money flow into HFGB could triple the value.
I was planning to buy a few more tomorrow but trying to visit their web site you get redirected to a porn site.Very disappointing development.
Not very many shares have traded below .08. Today's PR is encouraging, so I averaged down with a small buy today...the only one so far. Makes me wonder if I'm being a sucker.LOL. I had to call the order into my broker to place it...restricted from online placement! My only comment on that is that my swing trade success rate is pretty high on the trades I'm forced to call in to have a broker place....
Yawn. They sure are taking their time to file restated numbers. Pathetic.
I mentioned this before but it's worth stating again: I emailed with management just a few weeks ago and they're working on the financials. It's all systems go at HFGB and things are looking good for the stock price to rebound in a big way.
Huifeng Will Attend CPhI Worldwide Frankfurt 2011
Shaanxi Huifeng Pharmaceutical Co., Ltd. (the “Company”), the subsidiary of Huifeng Bio-Pharmaceutical Technology, Inc., will attend the CPhI Worldwide Frankfurt 2011 in Germany from Tuesday 25 October until Thursday 27 October 2011. CPhI Worldwide has been the world's leading pharmaceutical ingredients exhibition by providing unequalled business and networking opportunities, which is held annually and alternately in some European countries and is a great trade fair for global pharmaceutical companies. The Company will attend the CPhI Wordwide once again after successfully back from the CPhI China Exhibition held in Shanghai within this year. Being established for more than 10 years, the Company has received the national GMP certificate, the DMF registration number by FDA and the COS certificate by EDQM, and also won a good reputation and has a great influence in the national pharmaceutical raw materials and plant extracts industry. This exhibition will provide greater opportunities and broader market for the company's flagship product rutin and diosmin, and further, enable Huifeng to be global. Our booth number is 31C23, located in Hall 3.1, and the main exhibition products include Rutin, Troxerutin, Diosmin, Quercetin, Hesperidin, etc. We sincerely welcome all the customers, old and new, both at home and abroad to come to our booth to communicate and negotiate, and we will try our best to serve you.
huifeng ALIVE AND KICKING
new auditor and hopefulle again qtr figures
wow !!
If they get their accounting act straightned out and the restatements are close to the 8-K then I see no reason this won't go over $1.00 again. Maybe much more depending on the new clients they picked up in June.
.179 up. Time to move.
Just got in the door....was hoping to pick up some of them .13's.
Now only 5k left
Yep, he doesn't have much more.
NITE seller just abt finished here, next mm at .179
From June - check out the bold text. You think that may increade revenues and profits?
Huifeng Bio-Pharmaceutical Technology, Inc. ("Huifeng"), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives has successful attended the 11th CPhI China exhibition on June 21-23, 2011.
The 11th CPhI China 2011 was held on June 21 to June 23, 2011 at Shanghai New International Expo Center. The three-day exhibition built an effective platform for domestic enterprises and overseas buyers, and promoted the further escalation of the global market of raw materials and supplementary ingredients.This exhibition focused on the meetings aimed at the industry information exchange and market dynamics distribution. The topics of the laws and regulations, registration, quality standards and quality system certification of high-end European market are most favorable.
Eight members from Huifeng’s Sales Dep. and Marketing Dep. attended the exhibition. The visitors from domestic pharmaceutical companies, U.S., Europe, and other Asia countries visited our booth. During the exhibition, we received over 100 clients. Huifeng’s Diosmin with the European COS certificate received in May, 2011 and Rutin and Troxerutin with GMP certificate re-approved by SFDA draw more attention from the domestic and foreign customers. Huifeng has attended the CPhI China and Worldwide for many consecutive years, which made a good effect on our brand promotion and product sales. On the basis of solid foundation, standardized management and innovative thinking, Huifeng is developing further broad markets.
The new accountant announcement sold me on a few. I'll hold these for a while. Could provide a serious gain from down here.
IF/WHEN the new accountants prove out the adjustments in the 8-K this should be right back over .50 in a hurry....and IMO MUCH more going forward.
looks interesting. going to do some dd tommorow here
I grabbed a few. Looks interesting, and could see some nice gains from down here.
I emailed with management just last weekend and I feel comfortable we'll see those financials shortly.
great opportunity down here, w news and financials could easily be back over .70 which is around where most shares were bought...
I was surprised to receive a quick response from my email to Mrs. Bing He. Here is her reponse:
"Thank you for your email and support to Huifeng.
As you know, we filed an 8-K yesterday to show the engagement of a new independent accountant. The financial data will be coming.
We also got the COS certificate in May which was benefit to our sales. For more information, welcome to visit: www.hfgb.cn"
I'm taking this reply as a sign the company is still operating as normal and that they are happy to communicate with shareholders, a definite positive!
Well the news flow didn't exactly stop while they were looking for an auditor and I now expect the news flow to certainly pick up.
I emailed their office today to see if I could get some additional info. I'll let you know if I hear back.
First-time buyer on the auditor news, something that people have been waiting for a long time. EPS over .30, so this one has a long long ways to go upward. Company growing rapidly doesn't hurt either.
I'd say this is the best news we've heard in a long time!
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
302
|
Created
|
10/17/05
|
Type
|
Free
|
Moderators |
Huifeng Bio-Pharmaceutical Technology Inc. (“Huifeng”) develops, produces and sells plant extracts, pharmaceuticals and pharmaceutical raw materials in mainland China and internationally. Founded in 2000, the Company holds the patent for a highly efficient process to extract rutin, one of a class of plant-derived chemicals called flavonoids, with anti-inflammatory, antioxidant and anticoagulant properties. Other flavonoid or flavonoid-derived Huifeng products include troxerutin, quercetin, ginkgo biloba, diosmin and l-rhamnose. Manufacturers buy these products for use as the building blocks of drugs, dietary supplements and as additives in functional foods and beverages.
The Company’s production facilities are ISO9001:2000 certified, a necessary international qualification for export sales. The Company also holds a Chinese Good Manufacturing Practices (GMP) certification that allows it to distribute domestically. Products manufactured under GMP conditions have higher quality, consistency and potency assurances. Huifeng’s participation in PRC government biopharmaceutical industry initiatives entitles them to obtain funding to research new products.
Huifeng’s production efficiency has allowed them to become the dominant Chinese producer and exporter of rutin and to develop related products. In 2005, internal R&D efforts produced efficient methods of extracting diosmin and L-rhamnose, and they have recently expanded production facilities to manufacture these new products.
Huifeng has a diverse customer base, including distributors and manufacturers in China, Japan, Hong Kong, Russia, India, Germany, and the U.S. In the first 9 months of 2006, approximately 60% of products were sold in China and 40% were exported.
Huifeng BioPharmaceutical Technology, Inc.
FL16B, Ruixin Bldg, No.25 Gaoxin Rd., Xi'an 710075 China.
Press Release Source: Huifeng Bio-Pharmaceutical Technology, Inc. On Monday August 23, 2010, 7:30 am EDT
XI'AN, China, Aug. 23 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board:HFGB.ob -News), specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives today reiterated its financial results for its second quarter ended June 30, 2010.
Second Quarter 2010 Highlights
-- Revenue was $6,698,952, up 116.7% from the same quarter of 2009.
-- Gross profit was $2,467,064, up 109.5% from the second quarter of 2009
with gross margin of 36.8%, slightly decreased 1.3% from 38.1% for the
second quarter of 2009.
-- Net income was $1,532,302, an increase of $729,108 or 90.8% from the
second quarter 2009, and earnings per diluted share were $0.06 based on
25.4 million shares.
Second Quarter 2010 Results
Q2 2010 Q2 2009 CHANGE
Revenue $6.7 million $3.1 million +116.7%
Gross profit $2.5 million $1.2 million +109.5%
Net Income $1.5 million $0.8 million +90.8%
EPS (Diluted)* $0.06 $0.04 +50%
* Weighted average shares outstanding for Q2 2010 was 25,408,941 and for
Q2 2009 was 20,466,169."We are pleased to report record revenue and operating income in the quarter," Mr. Jing'an Wang, the Company's CEO, commented. "The large increase in profitability and top line growth can be attributed to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates. We have seen increased orders of both Rutin series products and Diosmin. We plan on focusing to fulfill the entire demand in the coming year."
For the Three Months Ended June 30, 2010 and 2009
Revenues for the quarter ended June 30, 2010 were $6,698,952, an increase of $3,607,427, or 116.7%, from$3,091,525 for the same quarter in 2009. Our increase in sales revenues for the second quarter of 2010 was mainly due to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates, which include our products of Rutin, Troxerutin, Quercetin and Diosmin. An analysis of our results in sales of our products is as follows:
For the quarter ended June 30
Product 2010 2009 Increase
Pharmaceutical intermediates $1,477,178 $765,929 $711,249
Pharmaceutical raw-material $4,712,016 $1,907,060 $2,804,956
Plant Extractive and others $509,758 $418,536 $91,222
TOTAL $6,698,952 $3,091,525 $3,607,427Our gross profit for the quarter ended June 30, 2010 was $2,467,064, an increase of $1,289,559, or 109.5%, from $1,177,505 for the same quarter in 2009 as a result of the increase in our products sold, mainly due to the sales increase of pharmaceutical raw-material.
Our gross margin as a percentage of revenues for 2010 slightly decreased 1.3% from 38.1% for the second quarter of 2009 to 36.8% in the same quarter in 2009, due to the slight increase in raw materials' price.
Net income for the quarter was $1,532,302, an increase of $729,108 or 90.8% from the second quarter of 2009, and earnings per diluted share were $0.06 based on 25.4 million shares.
For the Six Months Ended June 30, 2010 and 2009
Revenues for the six months ended June 30, 2010 were $10,850,838, an increase of $6,433,418, or 145.6%, from $4,417,420 for the same period in 2009. Our increase in revenues for the six months ended June 30, 2010was mainly due to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates, which include our products of Rutin, L-Rhamnose, Quercetin and Diosmin. An analysis of our results in sales of our products is as follows:
Six months ended June 30
Increase/
Product 2010 2009 (Decrease)
Pharmaceutical intermediates $2,309,996 $897,790 $1,412,206
Pharmaceutical raw-material $7,889,535 $2,635,525 $5,254,010
Plant Extractive and others $651,307 $884,105 $(232,798)
TOTAL $10,850,838 $4,417,420 $6,433,418The gross profit for the six months ended June 30, 2010 was $4,089,796, an increase of $2,638,236 or 181% from $1,451,560 for the six months period ended June 30, 2009 as a result of the increase in our products sold.
Our gross margin as a percentage of revenues for the six months ended June 30, 2010 was slightly increased from 32.9% to 37.7%, which compared to the same period in 2009. The increase in gross margin was mainly due to the increase of the selling price of raw-materials during the quarter ended June 30, 2010.
Net income for the first half of fiscal year 2010 was $2,396,191, compared to $410,557 in the prior year's corresponding period, a 483.6% increase year over year, and earning per diluted shares were $0.10 based on 25.1 million shares.
Financial condition
As of June 20, 2010, the Company had $1,661,815 in cash, increased from $85,105 in the prior year's corresponding period; working capital was $13,321,969. Cash provided by operating activities were $1,643,604, compared to cash used in operating activities of $106,697 for the six months ended June 30, 2009, mainly due to a decrease in accounts receivable and inventories of $171,204 and $1,173,837, respectively, as well as an increase due to a stockholder of Xi'an Runfeng Investment Ltd. of $497,117 and increase in our net income from continuing operations.
The Company reaffirms its 2010 Guidance
For the calendar year ended December 31, 2010, Huifeng reaffirms its $20.0-$25.0 million in revenue and $4.5-$5.0 in net income guidance respectively. The Company expects revenue and earnings growth to continue through the second half of the year, as it enters its most profitable selling period during the third and fourth quarter harvest and squeezing seasons.
About Huifeng Bio-Pharmaceutical Technology, Inc.
Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. More information can be found on the Company's web site at: http://www.hfgb.cn/
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors disclosed in the Company's Annual Report on Form 10K for the year ended Dec. 31, 2009 and all of the Company's subsequent Quarterly Reports on Form 10Q, especially in the "Risk Factors" sections of these reports. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Investor Relations:
Capital Group Communications, Inc.
Mr. Kevin Fickle
Tel: +1-925-330-8315
Email: Kevin@capitalgc.com
Company Contact:
Huifeng Bio-Pharmaceutical Technology, Inc.
Mr. Steven Tong, IR Director
Tel: +86-135-7211-8351
Email: Steven@xahuifeng.com
Kevin M Fickle
+415 644 5253 (Direct)
+415 332 7201 (Fax)
+925 330 8315 (Mobile)
kevin@nuwagroup.com
If you would like to speak to our sales staff, please email sales@xahuifeng.com or
fax our headquarters in Xi’an, China at 0086-29-88250444.
adam@adam-friedman.com or call 212-981-2529-x 18
Website: http://www.hfgb.cn
Company Officers:
Jing An Wang, CEO
Sanding Tao, CFO
Transfer Agent
Interwest Transfer Co., Inc.,
1981 E 4800 S.
Suite 100
Salt Lake City, UT 84117
Current Share Structure: updated as of March 19, 2008
Estimated Market Cap: $13,849,625.75
Outstanding Shares: 18,466,169
Number of Shareholders: 767
Approx Float: 2,100,000
Products:
Pharm.Raw Materials
Rutin Troxerutin Quercetin L-Rhamnone
Active Pharm.Ingredients
Silymarin Hesperidin Diosmin Matrine
Oxymatrine phytosterol Stigmasterol Pueraria
Reseveratrol Naringin Baicalin Berberine Hydrochlorrde.
10-Deacetyl Baccatin ? Paclitaxol
Plant Extracts
Epimedium Extract Ginkgo Biloba Leaf P.E Grape Seed.P.E Pueraria Lobata Extract
Magnolia P.E. Hawthorn Berry P.E. Bitter Melon P.E. Red Clover P.E.
chlorogenic acid Gynostema Extract Fructucs Aurantii P.E. Rhodiola Rosea P.E
Green Tea P.E.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |